Showing results (121-130 of 150) with videos related to

Sort By:
Pageof 15
Tumori|June 8, 2022
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)Caterina Caminiti, Jane Bryce, Silvia Riva, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 6, 2022
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief CommunicationSebastiano Buti, Umberto Basso, Diana Giannarelli, et al.
The Oncologist|November 20, 2025
Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25)Giandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
Clinical Genitourinary Cancer|May 22, 2024
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)Elisabetta Gambale, Marco Maruzzo, Carlo Messina, et al.
Cancer Immunology, Immunotherapy : CII|February 14, 2026
Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25Giandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
Targeted Oncology|May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
Frontiers in Immunology|June 29, 2026
Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) studyGiandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
The Oncologist|December 2, 2025
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort studyLorena Incorvaia, Mattia Puglisi, Marco Maruzzo, et al.
Minerva Urology and Nephrology|April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
JAMA Network Open|November 27, 2023
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving NivolumabMartina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, et al.
Pageof 15